Log In
Print
BCIQ
Print
Print this Print this
 

PUR0200

  Manage Alerts
Collapse Summary General Information
Company Pulmatrix Inc.
DescriptionInhaled dry powder formulation of a long-acting muscarinic receptor antagonist enabled by a non-lactose approach using Pulmatrix's iSPERSE delivery technology
Molecular Target Muscarinic receptor
Mechanism of ActionMuscarinic receptor antagonist
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationChronic obstructive pulmonary disease (COPD)
Indication DetailsTreat moderate chronic obstructive pulmonary disease (COPD)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today